Anesthetic drugs may affect renal perfusion; approach concomitant use of anesthetics and NSAIDs cautiously. Appropriate monitoring procedures should be employed during all surgical procedures. The use of peroperative parenteral fluids is recommended to decrease potential renal complications when using NSAIDs. If additional pain medication is needed after a single, one-time dose of MeloxiLab-Rat, a non-NSAID class of analgesics may be necessary.

Do not use MeloxiLab-Rat concomitantly with other anti-inflammatory drugs, such as NSAIDs or corticosteroids. NSAIDs possess the potential to produce gastrointestinal ulcerations and/or perforations.

Safety has not been established for intravenous (IV) or intramuscular (IM) administration in rats. The safe use of MeloxiLab-Rat has not been evaluated in breeding, pregnant, or lactating rats.

ADVERSE REACTIONS:

Adverse skin reactions around the injection site were observed in rats administered MeloxiLab-Rat at 4 mg/kg body weight. In a pilot study, 16/16 rats were observed to have skin lesions following a single subcutaneous injection of MeloxiLab-Rat at a dose of 4 mg/kg. Gross and histological findings showed erythema and localized inflammation, respectively, including 2 rats that developed draining tracts. The study reported that the median time rats developed a skin lesion was 3 days. (Stewart, 2020)

CONTACT INFORMATION:

To report adverse reactions or to obtain a copy of the SDS for this product call Wildlife Pharmaceuticals, Inc. at 1-970-795-0920.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDAVETS or http://www.fda.gov/reportanimalae.

CLINICAL PHARMACOLOGY:

Pharmacokinetic parameters of MeloxiLab-Rat were investigated in 7 male Sprague Dawley rats following a single subcutaneous injection of 4 mg/kg of body weight. Peak plasma concentrations of 18.5 mcg/mL at day 1 with rapid decrease in plasma concentrations starting at 48 hours post-dose with 5.9 mcg/mL, followed by 2.9 mcg/mL at 72 hours and 2.4 mcg/mL at 96 hours (Seymour, 2016).

Gender differences in rat meloxicam pharmacokinetics have been observed in fasted albino rats after IV and PO dosing (Busch 1998). After IV dosing at 1 mg/kg, the observed AUC infinity values were significantly higher for female (three-fold) versus male rats, and after repeated oral dosing at 0.3 or 1 mg/kg, females had 2.5 – 3.9 higher AUC infinity values than males. These gender differences appear to be due to differences in the rate of formation of oxidative metabolites, especially the carboxylic acid that is formed on the thiadiazole methyl group. There have been no other clinical studies to further assess pharmacokinetic gender differences among target animal species nor its clinical significance for effectiveness or safety using this drug formulation.

HOW SUPPLIED:

MeloxiLab-Rat is supplied in a 5 mL clear glass vial containing 2 mg meloxicam per mL.

STORAGE INFORMATION:

Store at controlled room temperature 15-30°C (59-86°F). Protect from sunlight and prolonged exposure to excessive heat.

Lot #:

Expiration Date:

Label Revision Date:

Manufactured for
Wildlife Pharmaceuticals, Inc.
1230 W. Ash Street, Suite D, Windsor, CO 80550

REFERENCES: